Integrin alpha M

Integrin alpha M (ITGAM) is one of the integrins, a large family of cell adhesion molecules that facilitate cell-cell interactions and cell-extracellular matrix (ECM) interactions. ITGAM is also commonly known as CD11b, a part of the CD system that classifies cluster of differentiation markers on the surface of cells. It forms a heterodimer with Integrin beta 2 (ITGB2), and the complex is known as Mac-1 or CR3 (complement receptor 3). This integrin plays a crucial role in the immune system, particularly in the processes of phagocytosis, inflammation, and leukocyte migration.

Structure

ITGAM, the alpha subunit, non-covalently pairs with the beta subunit (ITGB2) to form the integrin complex Mac-1. This complex is expressed on the surface of various leukocytes, including neutrophils, monocytes, macrophages, and natural killer cells. The ITGAM subunit is essential for the proper functioning of this receptor, as it mediates binding to various ligands, including iC3b, a component of the complement system, fibrinogen, ICAM-1, and others involved in the immune response and leukocyte adhesion.

Function

The primary function of ITGAM/CD11b is to mediate the adhesion of leukocytes to the endothelium and facilitate their migration from the bloodstream into tissues. This process is critical for the immune response to infection and injury. ITGAM is also involved in the phagocytosis of opsonized pathogens, a process enhanced by the activation of the complement system and the binding of its components to ITGAM. Additionally, ITGAM plays a role in the modulation of the immune response, including the activation of macrophages and the regulation of T-cell responses.

Clinical Significance

Mutations in the ITGAM gene can lead to a variety of immune system disorders. One of the most studied conditions is Systemic lupus erythematosus (SLE), an autoimmune disease where the immune system attacks its own tissues. Genetic variations in ITGAM have been associated with an increased risk of developing SLE, suggesting a role in the pathogenesis of autoimmune diseases. Furthermore, the expression levels of ITGAM can serve as a biomarker for the activation state of immune cells, particularly in inflammatory conditions.

Research and Therapeutic Applications

Given its central role in immune cell adhesion and migration, ITGAM is a target for therapeutic intervention in various diseases characterized by excessive inflammation or inappropriate immune responses. Inhibitors of ITGAM/CD11b interaction with its ligands are being explored as potential treatments for autoimmune diseases, inflammatory conditions, and in the prevention of ischemia-reperfusion injury. Research into the modulation of ITGAM function offers promising avenues for the development of novel immunotherapies.

This immune system related article is a stub. You can help WikiMD by expanding it.